Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease.

[1]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[2]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[3]  J. Rouleau,et al.  Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting enzyme (IMAGINE): a multicentre randomized trial - design and rationale. , 2002, The Canadian journal of cardiology.

[4]  R. Lees,et al.  The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. , 2001, The American journal of cardiology.

[5]  H. Crijns,et al.  Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. , 2001, The American journal of cardiology.

[6]  Y. Pinto,et al.  Angiotensin II Formation in Human Vasculature after Chronic ACE Inhibition: A Prospective, Randomized, Placebo-Controlled Study , 2000, Cardiovascular Drugs and Therapy.

[7]  M. Pfeffer,et al.  Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. , 1998, The American journal of cardiology.

[8]  Janzen,et al.  The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. , 1996, The Canadian journal of cardiology.

[9]  S. Yusuf,et al.  Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. , 1994, Circulation.

[10]  G. Lamas,et al.  Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. , 1994, Circulation.

[11]  B. Pitt,et al.  Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions , 1992, The Lancet.

[12]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[13]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[14]  C. Johnston,et al.  Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. , 1989, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[15]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.